Regeneron and Sanofi announce positive results from phase 2b study of dupilumab in patients with atopic dermatitis

Regeneron Pharmaceuticals, Inc.,¬†and Sanofi today announced positive results from a Phase 2b dose-ranging study of dupilumab, an investigational therapy, in adult patients with moderate-to-severe atopic dermatitis (AD), a serious, chronic (more…)

Read More